Who are Sitravatinib's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sutent, Cipterbin Combined With Vinorelbine, pirfenidone or nintedanib, TT-00420 (tinengotinib), OTX-TKI, Lenvatinib plus TACE.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sitravatinib.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Sitravatinib — Competitive Intelligence Brief

Sitravatinib (sitravatinib) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tyrosine kinase inhibitor. Area: Oncology.

marketed Tyrosine kinase inhibitor Tyrosine kinases Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Sitravatinib (sitravatinib) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sitravatinib TARGET	sitravatinib	Pfizer	marketed	Tyrosine kinase inhibitor	Tyrosine kinases
Sutent	Sunitinib Malate	Pfizer	marketed	Small molecule kinase inhibitor	Receptor tyrosine kinases (RTKs): PDGFRα, PDGFRβ, VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, CSF-1R, RET	2006-01-01
Cipterbin Combined With Vinorelbine	Cipterbin Combined With Vinorelbine	Zhejiang Cancer Hospital	marketed	Tyrosine kinase inhibitor combined with vinca alkaloid	Multiple tyrosine kinases (cipterbin); tubulin (vinorelbine)
pirfenidone or nintedanib	pirfenidone or nintedanib	Hospices Civils de Lyon	marketed	Antifibrotic agent	Pirfenidone: TGF-β pathway; Nintedanib: FGFR, VEGFR, PDGFR tyrosine kinases
TT-00420 (tinengotinib)	TT-00420 (tinengotinib)	TransThera Sciences (Nanjing), Inc.	phase 3	Multi-targeted tyrosine kinase inhibitor	VEGFR, FGFR, and other receptor tyrosine kinases
OTX-TKI	OTX-TKI	Ocular Therapeutix, Inc.	phase 3	Tyrosine kinase inhibitor	Multiple receptor tyrosine kinases (RTKs)
Lenvatinib plus TACE	Lenvatinib plus TACE	Second Affiliated Hospital of Guangzhou Medical University	phase 3	Multi-targeted tyrosine kinase inhibitor (in combination with transarterial chemoembolization)	FGFR, VEGFR, RET, KIT, and other receptor tyrosine kinases

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tyrosine kinase inhibitor class)

Jiangsu HengRui Medicine Co., Ltd. · 5 drugs in this class
Centre Leon Berard · 2 drugs in this class
AB Science · 2 drugs in this class
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 drugs in this class
Betta Pharmaceuticals Co., Ltd. · 1 drug in this class
Angion Biomedica Corp · 1 drug in this class
Beijing InnoCare Pharma Tech Co., Ltd. · 1 drug in this class
Chang-Ming Huang, Prof. · 1 drug in this class
Deciphera Pharmaceuticals, LLC · 1 drug in this class
AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sitravatinib — Competitive Intelligence Brief. https://druglandscape.com/ci/sitravatinib. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab